Concord Biotech Ltd IPO: Check IPO Date, Price, Details | Espresso


Concord Biotech Limited IPO opens on August 04. Check IPO Details Issue Date Price

August 03, 2023
Concord Biotech Limited IPO opens on August 04. Check IPO Details Issue Date Price

Concord Biotech Limited is coming out with a fresh public issue to raise Rs. 1550.52 crores from the market.

Below are the details of the Concord Biotech Limited Limited IPO:

  • Issue opens – August 04 (Friday)
  • Issue closes – August 08 (Tuesday)
  • Issue size – Rs. 1550.52 crores
  • Price band – Rs. 705 to 741 per equity share
  • Bid lot – 20 shares and in multiples thereof.

Heard about Pre-Apply IPO?

With Espresso’s Pre-Apply IPO feature, you can apply for IPOs before the start date or even after the market hours! Check out these easy-to-follow tutorials:

Quick Video Guides
How to Pre-Apply IPO on the appHow to Pre-Apply IPO on the website

Quick Visual Walkthroughs
How to Pre-Apply IPO on the appHow to Pre-Apply IPO on the website

And here are some details of the company and further details on the Concord Biotech Limited IPO.

  • Concord Biotech Limited is an India-based biopharma company and one of the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in 2022 (Source: F&S Report), supplying to over 70 countries including regulated markets, such as the United States, Europe and Japan, and India. They commanded a market share of over 20% by volume in 2022 across identified fermentation-based API products, including mupirocin, sirolimus, tacrolimus, mycophenolate sodium and cyclosporine. (Source: F&S Report) As of March 31, 2023, they had a total installed fermentation capacity of 1,250 m3. In 2016, they launched their formulation business in India as well as emerging markets, including Nepal, Mexico, Indonesia, Thailand, Ecuador, Kenya, Singapore and Paraguay, and have further expanded to the United States.
  • They manufacture (i) bio-pharmaceutical APIs through fermentation and semi-synthetic processes, across the therapeutic areas of immunosuppressants, oncology and anti-infectives; and (ii) formulations, which are used in the therapeutic areas of immunosuppressants, nephrology drugs and anti-infective drugs for critical care.
  • They are amongst the few companies globally that have successfully and sustainably established and scaled up fermentation-based API manufacturing capabilities (Source: F&S Report). As of March 31, 2023, they had six fermentation-based immunosuppressant APIs, including tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus and pimecrolimus.
  • They had filed 128 Drug Master Files (“DMFs”) across several countries for their APIs, including 20, 65 and four, respectively, in the United States, Europe and Japan, as of June 30, 2023. DMFs are documents filed by pharmaceutical manufacturers in respect of certain drug products, such as APIs, which contain proprietary information relating to such drug products.
  • In India, they market a portfolio of 27 brands across immunosuppressants, nephrology drugs and anti-infective drugs for critical care. They have a presence across 20 states and five union territories in India, through their sales team. They also have a B2B contract development manufacturing organization (“CDMO”) business where they supply immunosuppressants to the Indian market. Their immunosuppressant formulations are manufactured in facilities inspected or accredited by overseas regulators, such as the USFDA, and distributed to the United States and countries in Asia, Africa and Latin America on a B2B basis, primarily through arrangements with distributors.

Company details:

Issue Size: Rs. 1550.52 crores

Employee Reservation:

10,000 Equity shares amounting to Rs. 0.67/- crs

Employee Discount:

Rs. 70 Per Share

Net Issue break-up:

  • QIB – 50% of the offer –  Rs. 774.92 crores
  • NIB – 15% of the offer – Rs. 232.48 crores
  • RET – 35% of the offer – Rs. 542.45 crores

Listing: BSE and NSE

Registrar: Link Intime India Private Limited

UPI: All Retail & NII bidders' (bids up to Rs. 5,00,000) applications through brokers are compulsorily in UPI Mode.


  • Application made using third party UPI or ASBA Bank A/c are liable to be rejected. 
  • The UPI Mandate acceptance time for Retail and NII Bidders (bids up to Rs. 5,00,000) shall expire at 5:00 PM on the closing day of the IPO i.e. Monday, August 08, 2023     

Not an Espresso customer, but still want to apply for the Concord Biotech Limited IPO? Become an Espresso customer in just 15 mins* by tapping here and take it from there! (* T&C apply)

Team Espresso
by Team Espresso

We care that you succeed

Bringing readers the latest happenings from the world of Trading and Investments specifically and Finance in general.